Please assess the completion status of the following clinical trial:

Trial Title: Extended Analysis for Leukemia/Lymphoma Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. There are no further standard treatments available for the patient;~2. The patient has undergone at least two lines of previous therapy;~3. Cancer cell-containing biopsies are obtainable;~4. Informed consent from the patient was given;~5. candidate treatments identified by ngFDS are clinically available and considered safe given the patient health state.~Exclusion Criteria:~1. Presence of further treatment options, as defined by NCCN guidelines or Austrian guidelines representing a possible further treatment-related response by conventional therapies according to generally accepted medical evidence.~2. No fresh and viable tumor material available.~3. Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE v4.0) Grade 2 or higher from previous anti-cancer therapy, except alopecia.~4. Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.~5. A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.~6. A history of known glucose-6-phosphate dehydrogenase (G6PD) deficiency.~7. History of other malignancy. Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.~8. Uncontrolled medical conditions (i.e, diabetes mellitus, hypertension, etc), psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol; or unwillingness or inability to follow the procedures required in the protocol.~9. Pregnant or lactating females.~10. History of alcohol or drug abuse within 6 months prior to screening.~11. No informed consent available.~12. Exclusion criteria effective for respective treatment agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ngFDS selected treatment (Type: None): Treatment with commercially available treatments (per package insert instructions) chosen via next-generation functional drug screening (ngFDS).

Based on this trial design, predict the completion outcome and termination type (if applicable).